APA (7th ed.) Citation

N, J., JJ, L., Y, L., AA, M., C, H., J, W., . . . DB, C. (2022). Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease. Annals of neurology, 92(5), 729. https://doi.org/10.1002/ana.26511

Chicago Style (17th ed.) Citation

N, Joseph-Mathurin, et al. "Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease." Annals of Neurology 92, no. 5 (2022): 729. https://doi.org/10.1002/ana.26511.

MLA (9th ed.) Citation

N, Joseph-Mathurin, et al. "Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease." Annals of Neurology, vol. 92, no. 5, 2022, p. 729, https://doi.org/10.1002/ana.26511.